you know paul i've been thinking about this depiction i see the numbers i'm starting to think it may be one of the biggest and greatest drugs of all time and yet people are just discovering it can you talk about all the possible manifestations of this wonder drug you know it's for me at least i've been in the industry a long time this is a once in a generational medicine i talk to patients i talk to doctors about the benefits that this medicine brings we're privileged to be working with it um we go from copd asthma
atopic dermatitis chronic spontaneous odor carrier is in esophagitis we're pushing on the type 2 inflammatory diseases and a lot of these patients are really struggling with overlapping illnesses and not only that many amazing efficacy but incredible safety profile that's why we're seeing it grow over 70 percent even during a pandemic because physicians are happy to start it for patients who really need it because they know it's safe and it's incredibly effective and we think it's game-changing for those patients and indeed ultimately for the company i think that people when they hear monoclonal antibodies they want
to know well how is this made this is actually what a synthetic jug on your partner regeneron but it seems like that each each month there's some new thing that this thing works for that's not the way we're used to seeing drugs is is it like a living breathing organism that goes after different things you know we follow the science and we look at the patient need and we talk to those patients with autoimmune diseases and challenges from an immunology perspective and as we keep exploring and opening up these new patient populations we can really
help and we're willing to step in and do the work i mean it's just so important that we can transform these lives so we just keep pushing forward you know i told you i get letters every day about somebody's life that's been transformed somewhere by this medicine and we're just getting started and when you think about its role in our transformation when you think about the rest of our pipeline coming in behind and how 80 of it's going to be best or first in class we're really building something here you know and what adding to
it you know in terms of our acquisitions last year building our immunology so we really think we're going to have what patients need going forward and importantly really helping to transform this great company don't miss a second of mad money follow at jim kramer on twitter have a question tweet cramer hashtag mad tweets send jim an email to madmoney at cnbc.com or give us a call at 1-800-743-cnbc miss something head to madmoney.cnbc.com shepard smith here thanks for watching cnbc on youtube
